Phoenicia Biosciences, Inc.

Phoenicia Biosciences, Inc. is a Weston, Massachusetts biotechnology company developing therapeutics that modulate innate silenced genes to treat serious genetic blood diseases such as sickle cell disease and beta thalassemia, as well as viral-associated malignancies including Epstein-Barr Virus-associated lymphomas. The company has co-developed a next-generation therapeutic that suppresses three repressors of the fetal globin gene with the NCATS-TRND Program, which has been approved for a proof-of-concept clinical trial by the U.S. FDA and Health Canada. Phoenicia has also licensed its PKC delta inhibitor technology to Viracell Inc.